Test Bank For Clayton’s Basic Pharmacology for Nurses 19thEdition By Michelle J. Willihnganz, Samuel L. Gurevitz, Bruce Clayton Complete

Test Bank For Clayton’s Basic Pharmacology for Nurses 19th Edition By
v v v v v v v v v v



Michelle J. Willihnganz, Samuel L. Gurevitz, Bruce Clayton Complete
v v v v v v v v v

,Chapter 01: Drug Definitions, Standards, and Information Sources Willihnganz:
v v v v v v v v

Clayton’s Basic Pharmacology for Nurses, 19th Edition
v v v v v v v




MULTIPLEvCHOICE

1. WhichvnamevidentifiesvavdrugvlistedvbyvthevUSvFoodvandv
DrugvAdministrationv(FDA)?
a. Brand
b. Nonproprietary
c. Official
d. Trademark
ANS:vC
Thevofficialvnamevisvthevnamevundervwhichvavdrugvisvlistedvbyv
thevFDA.vThevbrandvname,vorvtrademark,visvthevnamevgivenvto
vavdrugvbyvitsvmanufacturer.vThevnonproprietary, vorvgeneric,vn

amevisvprovidedvbyvthevUnitedvStatesvAdoptedvNamesvCounci
l.

DIF: CognitivevLevel:vKnowledge REF:vp.v9
OBJ:v1NAT:vNCLEXvClientvNeedsvCategory:vSafe,vEffectivevCarev
EnvironmentvTOP:v NursingvProcessvStep:vAssessment
CON:v
PatientvEducation

2. Whichvsourcevcontainsvinformationvspecificvtovnutritionalsupplements?
a. USPvDictionaryvofvUSANv&vInternationalvDrugvNames
b. NaturalvMedicinesvComprehensivevDatabase
c. UnitedvStatesvPharmacopoeia/NationalvFormularyv(USPNF)
d. DrugvInteractionvFacts
ANS:vC
UnitedvStatesvPharmacopoeia/NationalvFormularyvcontainsvinformationvspecificvtovnutritionalvs
upplements.vUSPvDictionaryvofvUSANv&vInternationalvDrugvNamesvisvavcompilationvofvdrugvna
mes,vpronunciationvguide,vandvpossiblevfuturevFDAvapprovedvdrugs;vitvdoesvnotvincludevnutritio
nalvsupplements.vNaturalvMedicinesvComprehensivevDatabasevcontains
evidence-
basedvinformationvonvherbalvmedicinesvandvherbalvcombinationvproducts;vitvdoesvnotvincludevinf
ormationvspecificvtovnutritionalvsupplements.vDrugvInteractionvFactsvcontainsvcomprehensivevi
nformationvonvdrugvinteractionvfacts;vitvdoesvnotvincludevnutritionalvsupplements.

DIF: CognitivevLevel:vKnowledge REF:v p.v4
OBJ:v3vNAT:vNCLEXvClientvNeedsvCategory:vPhysiologicalvIntegr
ity
TOP:v NursingvProcessvStep:vAssessment CON:vNutritionv|vPatientvEducation

3. Whichvdrugvreferencevcontainsvdrugvmonographsvthatvdescribevallvdrugsvinvavtherapeuticvclass?
a. DrugvFactsvandvComparisons

, b. DrugvInteractionvFacts
c. HandbookvonvInjectablevDrugs
d. Martindale—ThevCompletevDrugvReference
ANS:vA
DrugvFactsvandvComparisonsvcontainsvdrugvmonographsvthatvdescribevallvdrugsvinvavth
erapeuticvclass.vMonographsvarevformattedvasvtablesvtovallowvcomparisonvofvsimilarvpro
ducts,vbrandvnames,vmanufacturers,vcostvindices,vandvavailablevdosagevformsvOnlinevve
rsionvisvavailable.

DIF: CognitivevLevel:vKnowledge REF:vp.v4vTablev1.2
OBJ:v v 3 NAT:vNCLEXvClientvNeedsvCategory:vPhysiologicalvIntegrity
TOP:v NursingvProcessvStep:vAssessment CON:vSafetyv|vPatientvEducationv|vClinicalvJudgment

4. Whichvdrugvreferencevcontainsvmonographsvaboutvvirtuallyveveryvsingle-
entitydrugvavailablevinvthevUnitedvStatesvandvdescribesvtherapeuticvusesvofvdrugs,vincludingvap
provedvandvunapprovedvuses?
a. Martindale:vThevCompletevDrugvReference
b. AHFSvDrugvInformation
c. DrugvReference
d. DrugvFactsvandvComparisons
ANS:vB
AHFSvDrugvInformationvcontainsvmonographsvaboutvvirtuallyveveryvsingle-
entityvdrugvavailablevinvthevUnitedvStatesvandvdescribesvtherapeuticvusesvofvdrugs,vincludingvapp
rovedvandvunapprovedvuses.

DIF: CognitivevLevel:vKnowledge REF:vp.v4vTablev1.2
OBJ:v v 3 NAT:vNCLEXvClientvNeedsvCategory:vPhysiologicalvIntegrity
TOP:v NursingvProcessvStep:vPlanning CON:vSafetyv|vPatientvEducationv|vClinicalvJudgment

5. Whichvonlinevdrugvreferencevmakesvavailablevtovhealthcarevprovidersvandvthevpublicvavstand
ard,vcomprehensive,vup-to-datevlookvupvandvdownloadablevresourcevaboutvmedicines?
a. AmericanvDrugvIndex
b. AmericanvHospitalvFormulary
c. DailyMed
d. DrugvReference
ANS:vC
DailyMedvmakesvavailablevtovhealthcarevprovidersvandvthevpublicvavstandard,vcomprehensive,v
up-to-
datevlookvupvandvdownloadablevresourcevaboutvmedicines.vThevAmericanvDrugvIndexvisvnotvapp
ropriatevforvpatientvuse.vThevAmericanvHospitalvFormularyvisvnotvappropriatevforvpatientvuse.vT
hevdrugvreferencevisvnotvappropriatevforvpatientvuse.

DIF: CognitivevLevel:vKnowledge REF:v p.v3v|p.v4
OBJ:v3vNAT:vNCLEXvClientvNeedsvCategory:vPhysiologicalvIntegr
ity
TOP:vNursingvProcessvStep:vImplementation
CON:vSafetyv|vPatientvEducationv|vClinicalvJudgment

6. WhichvlegislationvauthorizesvthevFDAvtovdeterminevthevsafetyvofvavdrugvbeforevitsvmarketing?
a. FederalvFood,vDrug,vandvCosmeticvActv(1938)
b. DurhamvHumphreyvAmendmentv(1952)

, c. ControlledvSubstancesvActv(1970)
d. KefauvervHarrisvDrugvAmendmentv(1962)

ANS:vA
ThevFederalvFood,vDrug,vandvCosmeticvActvofv1938vauthorizedvthevFDAvtovdeterminevthevsafety
vofvall vdrugsvbeforevmarketing.vLatervamendmentsvandvactsvhelpedvtightenvFDAvcontrolvandvensu

revdrugvsafety.vThevDurhamvHumphreyvAmendmentvdefinesvthevkindsvofvdrugsvthatvcannotvbevus
edvsafelyvwithoutvmedicalvsupervisionvandvrestrictsvtheirvsalevtovprescriptionvbyvavlicensedvpracti
tioner.vThevControlledvSubstancesvActvaddressesvonlyvcontrolledvsubstancesvandvtheirvcategoriz
ation.vThevKefauvervHarrisvDrugvAmendmentvensuresvdrugvefficacyvandvgreatervdrugvsafety.vDr
ugvmanufacturersvarevrequiredvtovprovevtovthevFDAvtheveffectivenessvofvtheirvproductsvbeforevm
arketingvthem.

DIF: CognitivevLevel:vKnowledge REF:vp.v5vTablevl.3
OBJ:v 5
NAT:vNCLEXvClientvNeedsvCategory:vPhysiologicalvIntegrityv
TOP:vNursingvProcessvStep:vAssessment
CON:vSafetyv|vPatientvEducationv|vEvidencev|vHealthvCarevLaw

7. Whichvclassificationvdoesvmeperidinev(Demerol)vfallvunder?
a. I
b. II
c. III
d. IV
ANS:vB
Meperidinev(Demerol)visvavSchedulevIIvdrug;vitvhasvavhighvpotentialvforvabusevandvmayvleadvtovse
verevpsychologicalvandvphysicalvdependence.vSchedulevIvdrugsvhavevhighvpotentialvforvabusevan
dvnovrecognizedvmedicalvuse.vSchedulevIIIvdrugsvhavevsomevpotentialvforvabuse.vUsevmayvleadvt
ovlowvtovmoderatevphysicalvdependencevorvhighvpsychologicalvdependence.vSchedulevIVvdrugsv
havevlowvpotentialvforvabuse.vUsevmayvleadvtovlimitedvphysicalvorvpsychologicalvdependence.

DIF: CognitivevLevel:vKnowledge REF:v p.v10
OBJ:v2vNAT:vNCLEXvClientvNeedsvCategory:vSafe,vEffectivevCare
vEnvironment

TOP:v NursingvProcessvStep:vAssessment CON:vPatientvEducationv|vAddictionv|vPain

8. WhichvactionvwouldvthevFDAvtakevtovexpeditevdrugvdevelopmentvandvapprovalvforvanvoutbreakvo
fvsmallpox?
a. Listvsmallpoxvasvavhealthvorphandisease.
b. Omitvthevpreclinicalvresearchphase.
c. Extendvthevclinicalvresearchvphase.
d. Fastvtrackvthevinvestigationalvdrug.
ANS:vD
OncevthevInvestigationalvNewvDrugvApplicationvhasvbeenvapproved,vthevdrugvcanvreceivevhigh
estvpriorityvwithinvthevagency,vwhichvisvcalledvfastvtracking.vAvsmallpoxvoutbreakvwouldvbeco
mevavpriorityvconcernvinvthevworld.vOrphanvdiseasesvarevnotvresearchedvinvavpriorityvmanner.vPr
eclinicalvresearchvisvnotvomitted.vExtendingvanyvphasevofvthevresearchvwouldvmeanvavlongervtim
evtovdevelopvavvaccine.vThevFDAvmustvensurevthatvallvphasesvofvthevpreclinicalvandvclinicalvresea
rchvphasevhavevbeenvcompletedvinvavsafevmanner.

DIF: CognitivevLevel:vKnowledge REF:v v p.v7 OBJ:v 5